Literature DB >> 770131

Clinical use of immunosuppressive drugs: part I.

N L Gerber, A D Steinberg.   

Abstract

While immunosuppressive drugs are principally used in the treatment of malignant disease, their use in non-malignant disease and transplantation has become commonplace. The mechanisms of action of immunosuppressive agents differ. Alkylating agents react with nucleophilic centres of D, and rna. Folic acid antagonists prevnt the conversion of dihydrofolic acid to tetrahydrofolic acid. Antibiotics act in a variety of different ways; the alkaloids cause metaphase arrest. Cytarabine (cytosine arabinoside), methotrexate, hydroxyurea and thioguanine act during mitosis and the latter also acts during replication is not known...

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 770131     DOI: 10.2165/00003495-197611010-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  119 in total

1.  Wegener's granulomatosis.

Authors:  J L FAHEY; E LEONARD; J CHURG; G GODMAN
Journal:  Am J Med       Date:  1954-08       Impact factor: 4.965

2.  Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy.

Authors:  J N Whitaker; W K Engel
Journal:  N Engl J Med       Date:  1972-02-17       Impact factor: 91.245

3.  Immunosuppressive drugs in the management of malignant and severe rheumatoid arthritis.

Authors:  M F Kahn; M Bedoiseau; S de Sèze
Journal:  Proc R Soc Med       Date:  1967-02

4.  Cyclophosphamide in lupus nephritis: a controlled trial.

Authors:  A D Steinberg; H B Kaltreider; P J Staples; E J Goetzl; N Talal; J L Decker
Journal:  Ann Intern Med       Date:  1971-08       Impact factor: 25.391

5.  Azathioprine in psoriasis.

Authors:  D D Munro
Journal:  Proc R Soc Med       Date:  1973-08

Review 6.  Immunosuppressants in the treatment of pemphigus.

Authors:  S Jablonska; T Chorzelski; M Blaszczyk
Journal:  Br J Dermatol       Date:  1970-08       Impact factor: 9.302

7.  Treatment of Wegener's granulomatosis with immunosuppressive agents. Description of renal ultrastructure.

Authors:  M A Aldo; M D Benson; F R Comerford; A S Cohen
Journal:  Arch Intern Med       Date:  1970-08

8.  Treatment of Reiter's syndrome with methotrexate.

Authors:  R L Jetton; W C Duncan
Journal:  Ann Intern Med       Date:  1969-02       Impact factor: 25.391

9.  Treatment of psoriasis with azathioprine.

Authors:  A Du Vivier; D D Munro; J Verbov
Journal:  Br Med J       Date:  1974-01-12

10.  Azathioprine in treatment of bullous pemphigoid.

Authors:  M W Greaves; J L Burton; J Marks; R P Dawber
Journal:  Br Med J       Date:  1971-01-16
View more
  5 in total

1.  Intractable Crohn's colitis and perianal disease responding to cyclophosphamide and epirubicin.

Authors:  N Rieger; J Stahl; D Wattchow
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

2.  Nitrogen mustard in severe rheumatoid arthritis.

Authors:  R Kitt; D L Scott; B L Coulton; A J Popert
Journal:  Clin Rheumatol       Date:  1983-03       Impact factor: 2.980

3.  In vivo protection by protein A of hepatic microsomal mixed function oxygenase system of cyclophosphamide-treated rats.

Authors:  M Dohadwala; P K Ray
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  Drug treatment of breast cancer.

Authors:  T E Davis; P P Carbone
Journal:  Drugs       Date:  1978-11       Impact factor: 9.546

5.  Rescue of rats from large dose cyclophosphamide toxicity using protein A.

Authors:  P K Ray; M Dohadwala; S K Bandyopadhyay; P Canchanapan; D McLaughlin
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.